MAHF selects Gideon, Davis, Parish, deRouin for 2005

The 2005 Medical Advertising Hall of Fame (MAHF) has selected four
industry leaders to be honored with induction, including David Gideon, the former publisher of Medical Marketing & Media, and Clifford Parish, a former pharmaceutical company executive.
Joining Gideon and Parish, the first pharma executive inducted into the Hall of Fame, are Clyde Davis and Sylvio (Sal) deRouin. Davis is a cofounder of Cline Davis & Mann, and he joins 2004 inductee Morgan Cline in the Hall of Fame. deRouin was a creative director at Rolf Werner Rosenthal Advertising, and Parish was director of advertising and promotion at Burroughs Wellcome Co. (now part of GlaxoSmithKline).
Posthumously, Milton Liebman, the former publisher of Hospital
Practice and a longtime contributing editor to MM&M, was named recipient of the Service to the Industry Award. Liebman passed away in December 2003. A black tie awards dinner will be held Feb. 8, 2005, at The Plaza Hotel in New York City.
This year's honorees were certified by MAHF's executive committee
following a vote of the organization's council of judges, which is comprised of leaders of the top healthcare
advertising agencies.
Gideon, who also founded media data company PERQ, teamed with
Euro RSCG Worldwide chairman and chief executive Ron Pantello to
co-found the Hall of Fame as a way to preserve the history of healthcare advertising. MAHF has honored medical advertising leaders annually since 1997, with 36 notables having been inducted.
You must be a registered member of MMM to post a comment.

Email Newsletters

What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.

A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.